ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

CIZ Cizzle Biotechnology Holdings Plc

1.90
0.00 (0.00%)
20 Jan 2025 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Cizzle Biotechnology Holdings Plc LSE:CIZ London Ordinary Share GB00BNG2VN02 ORD 0.01P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 1.90 1.80 2.00 1.90 1.90 1.90 327,508 07:47:49
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 0 -1.72M -0.0043 -4.42 7.53M
Cizzle Biotechnology Holdings Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker CIZ. The last closing price for Cizzle Biotechnology was 1.90p. Over the last year, Cizzle Biotechnology shares have traded in a share price range of 1.45p to 2.75p.

Cizzle Biotechnology currently has 396,390,000 shares in issue. The market capitalisation of Cizzle Biotechnology is £7.53 million. Cizzle Biotechnology has a price to earnings ratio (PE ratio) of -4.42.

Cizzle Biotechnology Share Discussion Threads

Showing 2226 to 2245 of 3075 messages
Chat Pages: Latest  99  98  97  96  95  94  93  92  91  90  89  88  Older
DateSubjectAuthorDiscuss
03/10/2023
11:39
How's the OBD short going ;-)
oapknob1
02/10/2023
07:15
"The test makes use of ProteinSimple's automated and highly sensitive immunoassay technology platform, Simple Western."

At a top level what is immunoassay technology ??

----

Ok, got it ...wonderful Wikipedia!

smithie6
02/10/2023
07:07
Somebody woke up and said "let's buy some CIZ" it seems ..
dplewis1
01/10/2023
11:24
Linked in - Bio-Techne love.

Could this UK spin-out from University of York hold the key for improved early detection of lung cancer and patient outcomes?

DirectorsTalk Interviews spoke to executive chairman Dr. Allan Syms from Cizzle Biotechnology plc about their collaboration with Bio-Techne to develop a new lung-cancer diagnostic test based on immunoassay technology.

Cizzle has developed a promising test to detect early-stage disease based on a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer.

The test makes use of ProteinSimple's automated and highly sensitive immunoassay technology platform, Simple Western.

This breakthrough comes at a time when the global market for lung cancer screening is expected to grow from US$2.8 billion in 2021 to US$4.85 billion by 2028.

Additionally, new US guidelines have expanded the number of people eligible for early lung cancer screening, potentially saving an extra 10,000 to 20,000 lives each year.

Congrats to Allan and the Cizzle team and my colleagues in Bio-Techne's analytical solutions division and our Bio-Techne UK office in Oxfordshire.

Helen Hall Katie Lloyd

#biomarkers #diagnostics #lungcancer

oapknob1
01/10/2023
05:15
The guy who wrote that first paragraph is Raymond chan of biotechne. No idea why he hides his name but one could imagine.
jimduggen
30/9/2023
21:33
Linked in - Bio-Techne love.Could this UK spin-out from University of York hold the key for improved early detection of lung cancer and patient outcomes? DirectorsTalk Interviews spoke to executive chairman Dr. Allan Syms from Cizzle Biotechnology plc about their collaboration with Bio-Techne to develop a new lung-cancer diagnostic test based on immunoassay technology.Cizzle has developed a promising test to detect early-stage disease based on a plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early-stage lung cancer. The test makes use of ProteinSimple's automated and highly sensitive immunoassay technology platform, Simple Western.This breakthrough comes at a time when the global market for lung cancer screening is expected to grow from US$2.8 billion in 2021 to US$4.85 billion by 2028.Additionally, new US guidelines have expanded the number of people eligible for early lung cancer screening, potentially saving an extra 10,000 to 20,000 lives each year.Congrats to Allan and the Cizzle team and my colleagues in Bio-Techne's analytical solutions division and our Bio-Techne UK office in Oxfordshire.Helen Hall Katie Lloyd#biomarkers #diagnostics #lungcancerListen to the interview:https://lnkd.in/eGXE-Vc6
oapknob1
29/9/2023
16:42
"Apta on the move!!"You got it right for once.It's down you clown!
secretsqu
29/9/2023
16:38
You mean Monday then??
not guilty
29/9/2023
15:04
Looks like the APTA pumpers backed the wrong pony! These young-ens will never learn.
the imperialist
29/9/2023
12:38
Naff off over there then.
secretsqu
29/9/2023
12:23
ZZZ till next month.Apta!!
thehitman1
29/9/2023
11:23
Apta on the move!!
thehitman1
29/9/2023
10:26
He sure can pick-em. I think the other members of the P&D crew left him holding the baby on APTA lol
the imperialist
29/9/2023
10:11
He is down 7% today alone on APTA
ddonaldson2
29/9/2023
10:06
Pump and dump
moneymachine2
29/9/2023
08:54
People taking their profits and buying back into Apta.
thehitman1
29/9/2023
08:54
Pump and dump in play.
thehitman1
29/9/2023
08:47
MoneyMachine has made his kebab money. Now for the real players to take over.
the imperialist
29/9/2023
08:46
Lol go back to losing money on APTA...
ddonaldson2
29/9/2023
08:45
Massive sell in the background,by the way.
moneymachine2
Chat Pages: Latest  99  98  97  96  95  94  93  92  91  90  89  88  Older